Cargando…

Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways

BACKGROUND: Targeted therapies are emerging treatment options for gastric cancer (GC). Patient-derived tumor xenograft(PDX) models of GC closely retain the features of the original clinical cancer, offering a powerful tool for preclinical drug efficacy testing. This study aimed to establish PDX GC m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haiyong, Lu, Jun, Tang, Jian, Chen, Shitu, He, Kuifeng, Jiang, Xiaoxia, Jiang, Weiqin, Teng, Lisong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348902/ https://www.ncbi.nlm.nih.gov/pubmed/28292264 http://dx.doi.org/10.1186/s12885-017-3177-9

Ejemplares similares

Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer
por: Lu, Jun, et al.
Publicado: (2015)

Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts
por: LIU, KAI, et al.
Publicado: (2015)

COL12A1, a novel potential prognostic factor and therapeutic target in gastric cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2019)

LncRNA MIR4435-2HG targets desmoplakin and promotes growth and metastasis of gastric cancer by activating Wnt/β-catenin signaling
por: Wang, Haiyong, et al.
Publicado: (2019)

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
por: Liu, Y J, et al.
Publicado: (2014)

BP-1-102 exerts an antitumor effect on the AGS human gastric cancer cell line through modulating the STAT3 and MAPK signaling pathways
por: Jiang, Xiaoxia, et al.
Publicado: (2019)

Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study
por: Yu, Xiongfei, et al.
Publicado: (2022)

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
por: KATO, HIROAKI, et al.
Publicado: (2013)

GPRC5A: An Emerging Biomarker in Human Cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2018)

Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis
por: Ye, Peng, et al.
Publicado: (2015)

Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation
por: Saisana, Marina, et al.
Publicado: (2016)

Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target
por: Du, Xiaoxiao, et al.
Publicado: (2020)

Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend
por: Zhang, Jing, et al.
Publicado: (2020)

Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer
por: Gu, Yu, et al.
Publicado: (2016)

HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2018)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis
por: Lin, Wu, et al.
Publicado: (2023)

Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies
por: Zhang, Xu-chao, et al.
Publicado: (2013)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations
por: Uehara, Yuji, et al.
Publicado: (2022)

Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models
por: Chen, Xiangheng, et al.
Publicado: (2018)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis (Adv. Sci. 30/2023)
por: Lin, Wu, et al.
Publicado: (2023)

A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts
por: Paquette, Michel, et al.
Publicado: (2020)

Overexpressed MAGP1 Is Associated With a Poor Prognosis and Promotes Cell Migration and Invasion in Gastric Cancer
por: Wu, Mengjie, et al.
Publicado: (2020)

Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study
por: Yasui, Hisateru, et al.
Publicado: (2022)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

LncRNA UCA1 in anti-cancer drug resistance
por: Wang, Haohao, et al.
Publicado: (2017)

A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins
por: Zdobnova, Tatiana, et al.
Publicado: (2015)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade
por: Singh, Rohit, et al.
Publicado: (2013)

MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells
por: Kitowska, Kamila, et al.
Publicado: (2021)

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
por: Chen, Shinan, et al.
Publicado: (2018)

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
por: Gaibar, María, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
por: Jiang, Haiping, et al.
Publicado: (2022)

Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors
por: Yıldız, Yetkin, et al.
Publicado: (2016)

HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target
por: Fong, Caroline, et al.
Publicado: (2022)

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
por: Xiang, Hong, et al.
Publicado: (2021)

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases
por: Jin, Ketao, et al.
Publicado: (2011)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies
por: Ojima, Hidenori, et al.
Publicado: (2016)

Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study
por: Xu, Chang, et al.
Publicado: (2022)

Identification of TYROBP and C1QB as Two Novel Key Genes With Prognostic Value in Gastric Cancer by Network Analysis
por: Jiang, Junjie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lov0qamjg1agfmcgsjulr93p57